Oncology

Oncology is the branch of medicine and biomedical science dedicated to the etiology, prevention, molecular diagnosis, anatomical staging, and multimodal treatment of cancer and related neoplasms. Derived from the Classical Greek onkos (meaning bulk, mass, or tumor) and logos (study), the field bridges laboratory investigation of cellular transformation with clinical care and population-level public health surveillance. Because malignant neoplasms arise through the somatic evolution of cells that acquire heritable mutations and epigenetic alterations, clinical oncology coordinates three primary subspecialties—medical oncology, surgical oncology, and radiation oncology—alongside diagnostic pathology, interventional radiology, and palliative medicine.

Malignant transformation occurs when a clonal lineage of somatic cells accumulates genetic and epigenetic alterations that uncouple proliferation from homeostatic tissue signaling, bypass checkpoints of the cell cycle, and suppress programmed cell death via apoptosis. Although individual tumors exhibit wide mutational heterogeneity, driver alterations converge onto two functional gene classes: proto-oncogenes and tumor suppressor genes.

Oncogene Activation and Gain-of-Function Drivers

Proto-oncogenes encode physiological regulators of mitogenic signal transduction, receptor tyrosine kinase activity, guanosine triphosphate (GTP) hydrolysis, and transcriptional activation. Converting a proto-oncogene into an active oncogene requires only a single dominant gain-of-function event—such as a missense point mutation, chromosomal translocation, or focal gene amplification—that renders the encoded protein constitutively active or overexpressed. Classic point mutations include substitutions at codons 12, 13, or 61 of KRAS, NRAS, and HRAS, which impair intrinsic GTPase activity and lock the RAS protein in an active GTP-bound conformation that drives mitogen-activated protein kinase (MAPK) signaling. Receptor tyrosine kinase amplification is exemplified by ERBB2 (HER2) copy-number gains in breast and gastric adenocarcinomas, as well as activating exon 19 deletions or L858R substitutions in EGFR in lung adenocarcinoma. Chromosomal rearrangements either place a transcription factor under an active enhancer—such as t(8;14)(q24;q32) juxtaposing MYC to the immunoglobulin heavy-chain locus in Burkitt lymphoma—or generate chimeric fusion kinases such as the Philadelphia chromosome t(9;22)(q34;q11) encoding BCR-ABL1 in chronic myeloid leukemia.

Tumor Suppressor Inactivation and the Two-Hit Hypothesis

Tumor suppressor genes encode gatekeepers that restrain cell division, enforce cell-cycle checkpoints, or execute DNA repair and apoptotic elimination. Following Alfred Knudson's 1971 two-hit hypothesis formulated from familial versus sporadic retinoblastoma, both maternal and paternal alleles must be inactivated through point mutation, frameshift insertion/deletion, loss of heterozygosity (LOH), or promoter CpG hypermethylation to abolish function. The retinoblastoma protein (pRb, encoded by RB1) sequesters E2F transcription factors until phosphorylated by CDK4/6 and CDK2 at the G₁/S restriction point. The transcription factor p53 (TP53), mutated in over 50% of solid tumors, senses DNA breaks and oncogenic stress, inducing the CDK inhibitor p21 (CDKN1A) or upregulating pro-apoptotic BCL-2 members (BAX, PUMA, NOXA). Loss of the lipid phosphatase PTEN prevents conversion of PIP₃ to PIP₂, activating PI3K–AKT–mTOR signaling, whereas biallelic inactivation of APC stabilizes β-catenin in colorectal epithelium. Caretaker suppressors (BRCA1, BRCA2, MLH1, MSH2) preserve genomic integrity; their loss elevates somatic mutation rates.

The Hallmarks of Cancer Framework

In 2000 and 2011, Douglas Hanahan and Robert Weinberg synthesized the diverse genotypes of human malignancies into the hallmarks of cancer framework:

• Sustained proliferative signaling: Autocrine growth factor production, receptor overexpression, or constitutive activation of RAS–RAF–MEK–ERK and PI3K–AKT cascades.
• Evasion of growth suppressors: Inactivation of RB1, TP53, and transforming growth factor-beta (TGF-β) antiproliferative pathways.
• Resistance to cell death: Overexpression of anti-apoptotic BCL-2, BCL-X_L, or MCL-1, or loss of pro-apoptotic mitochondrial sensors.
• Enabling replicative immortality: Reactivation of telomerase reverse transcriptase (TERT) in ~85–90% of malignancies, or alternative lengthening of telomeres (ALT).
• Induction of angiogenesis: HIF-1α-mediated transcription of vascular endothelial growth factor A (VEGF-A) to vascularize tumors beyond the 1–2 mm oxygen diffusion limit.
• Activation of invasion and metastasis: Downregulation of E-cadherin (CDH1), execution of the epithelial-to-mesenchymal transition (EMT), matrix metalloproteinase stromal degradation, intravasation, and distant colonization.
• Deregulated cellular energetics and immune evasion: Reprogramming glucose metabolism toward aerobic glycolysis (the Warburg effect) paired with suppression of antitumor immunology surveillance.

Neoplasms are grouped into five histogenetic categories according to their cell of origin: (1) Carcinomas (~80–85% of adult malignancies) arising from epithelial sheets, subdivided into glandular adenocarcinomas (colon, breast, prostate, pancreas, lung) and squamous cell carcinomas (epidermis, esophagus, head and neck, cervix); (2) Sarcomas (~1–2% of adult cancers, ~15% of pediatric malignancies) arising from mesenchymal tissues including bone (osteosarcoma), cartilage (chondrosarcoma), muscle (leiomyosarcoma, rhabdomyosarcoma), and fat (liposarcoma); (3) Leukemias arising from marrow hematopoietic progenitors; (4) Lymphomas and myeloma arising from B, T, or NK lymphocytes and plasma cells; and (5) Central nervous system and neuroectodermal neoplasms (glioblastoma, melanoma, neuroblastoma).

Diagnostic Pathology and Liquid Biopsy

Definitive diagnosis requires histopathological and immunohistochemical examination of biopsy or resection tissue. Pathologists assign a histologic grade (G1 to G4, or the Gleason score in prostate cancer) based on differentiation, nuclear pleomorphism, and mitotic index, supplemented by next-generation sequencing (NGS) and fluorescence in situ hybridization (FISH). Minimally invasive liquid biopsies isolate cell-free circulating tumor DNA (ctDNA) shed into plasma by tumor cells. Digital droplet PCR and hybrid-capture sequencing of ctDNA detect actionable resistance mutations (such as EGFR T790M), quantify minimal residual disease (MRD) after surgery, and monitor clonal evolution longitudinally.

Anatomical Staging and the TNM System

Whereas grading assesses cellular differentiation microscopically, staging quantifies the macroscopic anatomical extent of disease via the AJCC/UICC TNM staging system: T (Primary Tumor) scores lesion size and local invasion depth from T_is (in situ) through T1–T4; N (Regional Lymph Nodes) records the absence (N0) or extent of regional lymph node metastases (N1–N3); and M (Distant Metastasis) records the absence (M0) or presence (M1) of distant organ dissemination. Combined with biological biomarkers, TNM descriptors define Stage 0 (in situ), Stages I–III (localized and locoregionally advanced disease), and Stage IV (metastatic disease), evaluated using CT, MRI, and ¹⁸F-FDG PET/CT.

Cancer therapy combines local-regional control with systemic eradication of micrometastases, scheduled as neoadjuvant (preoperative), adjuvant (postoperative), definitive (primary curative radiation/chemoradiation), or palliative care.

Surgical and Radiation Oncology

Surgical resection removes the tumor with a margin of uninvolved tissue to achieve a negative margin (R0 resection, vs. R1 microscopic and R2 macroscopic residual disease), aided by sentinel lymph node biopsy in breast cancer and melanoma. Radiation oncology delivers ionizing radiation measured in gray (Gy) (1 J kg⁻¹) via linear accelerators (4–25 MV photons), brachytherapy (¹⁹²Ir, ¹²⁵I), or proton beams. Ionizing radiation induces DNA double-strand breaks directly and via water-radiolysis hydroxyl radicals (^•OH) fixed by molecular oxygen. Fractionation (50–70 Gy in 1.8–2.0 Gy daily fractions) exploits the four Rs of radiobiology: normal-tissue repair, cell-cycle reassortment, tumor reoxygenation, and repopulation.

Systemic Pharmacology and Immunotherapy

Systemic medical oncology and precision oncology guided by companion diagnostics utilize three therapeutic classes: (1) Cytotoxic chemotherapy, including DNA-crosslinking platinum and alkylating agents (cisplatin, cyclophosphamide), antimetabolites (5-fluorouracil and thiopurines guided by thiopurine and fluoropyrimidine pharmacogenetics, methotrexate), topoisomerase poisons (irinotecan guided by UGT1A1 pharmacogenetics, doxorubicin), and microtubule inhibitors (paclitaxel); (2) Targeted therapy, inaugurated by imatinib (BCR-ABL1) and expanded to monoclonal antibody therapy (trastuzumab), antibody-drug conjugates (trastuzumab deruxtecan), small-molecule tyrosine kinase inhibitors (osimertinib, sotorasib), targeted protein degradation, and synthetic lethality and PARP inhibitors (olaparib) in BRCA1/2-mutant tumors; and (3) Cancer immunotherapy, utilizing CTLA-4 and PD-1/PD-L1 immune checkpoint inhibitors alongside engineered CAR-T cell therapy targeting CD19 or BCMA. Primary prevention (tobacco cessation; HPV and HBV vaccination) and secondary screening (low-dose CT, mammography, HPV testing, colonoscopy) reduce population mortality.

What is the difference between a benign tumor and a malignant neoplasm?

A benign tumor (such as a uterine leiomyoma, colonic tubular adenoma, or cutaneous lipoma) consists of well-differentiated cells that proliferate locally within a fibrous capsule or basement membrane without invading adjacent tissues or spreading to distant sites. Although benign tumors can cause clinical morbidity if they compress vital structures in the cranium or secrete excess hormones, local surgical excision is usually curative. A malignant neoplasm (cancer), by contrast, breaches the epithelial basement membrane, infiltrates surrounding stroma, and can enter lymphatic or blood vessels to establish distant metastases.

Why do tumors develop resistance to targeted therapies and chemotherapy?

Large solid tumors contain billions of genetically and epigenetically diverse cells undergoing continuous Darwinian selection. Under the selective pressure of a systemic drug, rare pre-existing subclones or newly mutated cells survive and expand. Resistance mechanisms include secondary mutations in the target kinase drug-binding pocket (such as EGFR T790M or C797S and BCR-ABL1 T315I), activation of parallel bypass signaling pathways (such as MET amplification), upregulation of ATP-binding cassette (ABC) efflux pumps like P-glycoprotein (ABCB1), and lineage plasticity (such as transdifferentiation of EGFR-mutant lung adenocarcinoma into small-cell neuroendocrine carcinoma).

How does the TNM stage differ from the histological grade of a tumor?

Histological grade is a microscopic assessment performed by a pathologist on biopsy or resection tissue; it describes how closely the tumor cells resemble normal differentiated tissue (from well-differentiated Grade 1 to undifferentiated or anaplastic Grade 4) and reflects intrinsic cellular aggressiveness. Anatomical stage (expressed via the TNM system from Stage I to Stage IV) is a macroscopic measurement of where the cancer is located in the body—measuring primary tumor size and depth (T), regional lymph node spread (N), and distant organ metastasis (M)—integrating physical examination, imaging, and surgical pathology.

1. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013
2. Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., Jr., & Kinzler, K. W. (2013). Cancer genome landscapes. Science, 339(6127), 1546–1558. https://doi.org/10.1126/science.1235122
3. Knudson, A. G., Jr. (1971). Mutation and cancer: Statistical study of retinoblastoma. Proceedings of the National Academy of Sciences, 68(4), 820–823. https://doi.org/10.1073/pnas.68.4.820
4. Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017). The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA: A Cancer Journal for Clinicians, 67(2), 93–99. https://doi.org/10.3322/caac.21388